Previous Article | Next Article ![]()
Journal of Clinical Microbiology, April 2001, p. 1254-1257, Vol. 39, No. 4
Department of Pathology, Johns Hopkins
Medical Institutions, Baltimore, Maryland1;
Department of Pediatrics, University of California at Los
Angeles School of Medicine, Los Angeles,2 and
Applied Biosystems, Foster City,5
California; Department of Pediatrics, University of Medicine
and Dentistry of New Jersey, Newark, New
Jersey3; and Statistical Data Analysis
Center, Harvard School of Public Health, Boston,
Massachusetts4
Received 6 November 2000/Returned for modification 18 December
2000/Accepted 15 January 2001
The ViroSeq HIV-1 Genotyping System is a commercially available,
integrated sequence-based system for analysis of human immunodeficiency virus type 1 (HIV-1) drug resistance. We evaluated the performance of
this system by analyzing HIV-1 in pediatric plasma samples. Plasma
samples from children 4 months to 17 years of age were obtained from a
clinical trial protocol (PACTG 377). Children in PACTG 377 were
randomized to four treatment arms, including different combinations of
antiretroviral drugs. HIV-1 genotyping was performed using samples
collected prior to antiretroviral therapy (baseline) and at the time of
virologic failure. Performance of the genotyping system was compared in
three university laboratories. A total of 196 samples were analyzed,
including 135 baseline and 61 failure samples. Plasma volumes ranged
from 0.05 to 0.5 ml, and viral loads ranged from 1,084 to 3,484,991 copies/ml. PCR products suitable for sequencing were obtained for 192 of the 196 samples. Complete sequences for protease and reverse
transcriptase were obtained for all of these 192 samples. For 180 samples, data were obtained from both DNA strands for the entire region
analyzed. There was no evidence of sample cross-contamination based on
phylogenetic analysis of HIV-1 sequences. Performance of the genotyping
system was similar in three laboratories. This genotyping system
performs well for analysis of HIV-1 in pediatric plasma samples,
including those with low volume and low viral load. The availability of this system should facilitate studies of HIV-1 drug resistance.
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.4.1254-1257.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Performance of the Applied Biosystems ViroSeq Human
Immunodeficiency Virus Type 1 (HIV-1) Genotyping System for
Sequence-Based Analysis of HIV-1 in Pediatric Plasma
Samples
*
Corresponding author. Mailing address: Department of
Pathology, The Johns Hopkins Medical Institutions, Ross Bldg. 646, 720 Rutland Ave., Baltimore, MD 21205. Phone: (410) 614-4734. Fax: (410)
614-3548. E-mail: seshlem{at}jhmi.edu.
This article has been cited by other articles:
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|